期刊文献+

乳腺癌新辅助化疗前后超声造影表现 被引量:10

CEUS performance of breast cancer before and after neoadjuvant chemotherapy
下载PDF
导出
摘要 目的探讨乳腺癌新辅助化疗前后的超声造影表现。方法将接受乳腺癌新辅助化疗(NAC)的31例患者作为研究对象,以术前的穿刺病理和术后的手术病理为参照标准,比较化疗前后肿瘤的超声造影增强模式,并应用时间-强度曲线分析软件对参数进行分析。结果乳腺癌NAC前后,肿瘤的CEUS类型以不均匀增强为主[化疗前(18/31,58.06%),化疗后(21/31,67.74%)],化疗后无增强的肿瘤明显增多[(化疗前0,化疗后(5/31,16.13%)]。造影参数分析:化疗后的上升时间增加,峰值强度及曲线下面积降低,差异均有统计学意义(P均<0.05)。结论乳腺癌NAC前后,肿瘤的CEUS增强类型以不均匀增强为主,化疗后无增强的比例明显增高。化疗前后肿瘤CEUS的时间-强度曲线指标中,上升时间、峰值强度和曲线下面积是有价值的指标。 Objective To investigate the CEUS performance of breast cancer before and after neoadjuvant chemotherapy(NAC).Methods A total of 31 patients receiving NAC were taken as research object.Pre-operative biopsy and post-operative surgical pathologies were taken as the reference standard.CEUS performance before and after NAC were compared,and the time-intensity curve of the tumor was analyzed.Results The inhomogeneous enhancement was typical in CEUS before and after NAC(58.06% [18/31]and 67.74% [21/31]),without non-enhancement.While after NAC,the number of non-enhancement tumor significantly increasesd(5/31,16.13%).As for the mass parameter,the rise time,peak intensity and area under the curve before and after the NAC had statistical significance(all P〈0.05).Conclusion After the NAC,enhancement type of CEUS of breast cancer is mainly inhomogeneous and the rate of non-enhancement significantly increases.Gamma-variate analysis shows statistically significant differences in rise time,peak intensity and area under the curve before and after NAC.
出处 《中国介入影像与治疗学》 CSCD 北大核心 2015年第1期52-55,共4页 Chinese Journal of Interventional Imaging and Therapy
关键词 乳腺肿瘤 超声检查 抗肿瘤联合化疗方案 时间-强度曲线 Breast neoplasms Ultrasonography Antineoplastic combined chemotherapy protocols Time-intensity curve
  • 相关文献

参考文献11

  • 1Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. CA Cancer J Clin, 2009,59(4) :225-249.
  • 22009年上海市市区恶性肿瘤发病率[J].肿瘤,2012,32(10):854-854. 被引量:15
  • 3刘赫,姜玉新,刘吉斌,朱庆莉,孙强,常晓燕.乳腺病变超声造影微血管显像增强形式:与病理对照观察[J].中国医学影像技术,2009,25(5):783-785. 被引量:24
  • 4Mamounas EP, Wang J, Bryant J, et al. Patterns of loco-regional failure (LRF) in patients receiving neoadiuvant chemotherapy (NC): Results from NSABP B-18. Breast Cancer Res Treat, 2003,82(1) :S17.
  • 5Goldhirseh A, Wood WC, Senn HJ, et al. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J ClinOncol, 1995,87(19) :1441- 1445.
  • 6Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer, 2002,95(4): 681-695.
  • 7Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadiuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol, 2005,184(3) :868-877.
  • 8Kedar RP, Cosgrove D, Mccready VR, et ai. Microbubble con- trast agent for color Doppler US: Effect on breast masses. Work in progress. Radiology, 1996,198(3) :679-686.
  • 9Huber S, Helbich T, Kettenbach J, et al. Effects of a microbub- ble contrast agent on breast tumors: Computer-assisted quantita- tive assessment with color Doppler US-early experience. Radiol- ogy, 1998,208(2) :485-489.
  • 10Stamm C, Westphal B, Kleine HD, et al. Autologous bone- marrow stem-cell transplantation for myocardial regeneration. Lancet, 2003,361(9351) :45-46.

二级参考文献7

共引文献37

同被引文献85

  • 1曹小丽,刘瑞华,刘美娟,曹立萍,王丽红,张玉莲.乳腺癌患者超声造影表现及其与微血管密度的关系[J].中华医学超声杂志(电子版),2013,10(7):590-595. 被引量:14
  • 2杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1504
  • 3Siegel R,Ward E, Brawley 0,et al. Cancer statistics, 2011 :The impact of eliminating socioeconomic and racial disparities onpremature cancer deaths. CA Cancer J Clin, 2011, 61 (4):212-236.
  • 4Cha JH, Moon WK, Cho N, et al. Differentiation of benign frommalignant solid breast masses: Conventional US versus spatialcompound imaging. Radiology, 2005,237(3) :841-846.
  • 5Muir TE, Cheville JC, Lager DJ. Metanephric adenoma, nephro-genic rests, and Wilms' tumor: A histologic and immunopheno-typic comparison. Am J Surg Pathol, 2001, 25(10) : 1290-1296.
  • 6Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases.Nature, 2000,407(6801):249-257.
  • 7Wan CF, Du J, Fang H, et al. Enhancement patterns and param-eters of breast cancers at contrast-enhanced US: Correlation withprognostic factors. Radiology, 2012,262(2) :450-459.
  • 8Wenhua D, Lijia L, Hui W, et al. The clinical significance ofreal-time contrast-enhanced ultrasonography in the differentialdiagnosis of breast tumor. Cell Biochem Biophys, 2012, 63(2):117-120.
  • 9Saracco A, SzaboBK, Aspelin P, et al. Differentiation betweenbenign and malignant breast tumors using kinetic features of re-al-time harmonic contrast-enhanced ultrasound. Acta Radiol,2012,53(4):382-388.
  • 10Wang X,Xu P, Wang Y, et al. Contrast-enhanced ultrasono-graphic findings of different histopathologic types of breast canc-er. Acta Radiol, 2011, 52(3) : 248-255 .

引证文献10

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部